663 related articles for article (PubMed ID: 18551021)
1. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
2. Endothelial damage due to impaired nitric oxide bioavailability triggers cerebral aneurysm formation in female rats.
Tamura T; Jamous MA; Kitazato KT; Yagi K; Tada Y; Uno M; Nagahiro S
J Hypertens; 2009 Jun; 27(6):1284-92. PubMed ID: 19307983
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
[TBL] [Abstract][Full Text] [Related]
5. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
6. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
[TBL] [Abstract][Full Text] [Related]
7. Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemia-reperfusion: role of angiotensin II.
Gemici B; Tan R; Ongüt G; Izgüt-Uysal VN
J Surg Res; 2010 Jun; 161(1):126-33. PubMed ID: 19959193
[TBL] [Abstract][Full Text] [Related]
8. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels.
Fujita T; Hirooka K; Nakamura T; Itano T; Nishiyama A; Nagai Y; Shiraga F
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4099-110. PubMed ID: 22661470
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors.
Faure S; Bureau A; Oudart N; Javellaud J; Fournier A; Achard JM
J Hypertens; 2008 Oct; 26(10):2008-15. PubMed ID: 18806625
[TBL] [Abstract][Full Text] [Related]
11. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
12. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats.
Bennai F; Morsing P; Paliege A; Ketteler M; Mayer B; Tapp R; Bachmann S
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S104-15. PubMed ID: 9892150
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
[TBL] [Abstract][Full Text] [Related]
14. Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation.
Liu H; Liu X; Wei X; Chen L; Xiang Y; Yi F; Zhang X
Brain Res Bull; 2012 Oct; 89(1-2):65-70. PubMed ID: 22766267
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor.
Thai H; Wollmuth J; Goldman S; Gaballa M
J Pharmacol Exp Ther; 2003 Dec; 307(3):1171-8. PubMed ID: 14560036
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys.
Yoshioka I; Tsujihata M; Akanae W; Nonomura N; Okuyama A
Urology; 2011 Apr; 77(4):1007.e9-1007.e14. PubMed ID: 21256551
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
[TBL] [Abstract][Full Text] [Related]
18. An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats.
Oyama N; Yagita Y; Sasaki T; Omura-Matsuoka E; Terasaki Y; Sugiyama Y; Sakoda S; Kitagawa K
J Neurosci Res; 2010 Oct; 88(13):2889-98. PubMed ID: 20544833
[TBL] [Abstract][Full Text] [Related]
19. Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.
Lange SA; Wolf B; Schober K; Wunderlich C; Marquetant R; Weinbrenner C; Strasser RH
J Cardiovasc Pharmacol; 2007 Jan; 49(1):46-55. PubMed ID: 17261963
[TBL] [Abstract][Full Text] [Related]
20. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
